US Edition
News from Sickle Cell Disease Association of America Inc.
Top Sickle Cell Disease Association of America Inc. News
FDAPfizer Inc. (NYSE:PFE) on Friday released results from the Phase 3 THRIVE-131 study evaluating inclacumab, an investigational P-selectin inhibitor, in patients 16 years of age and older with sickle cell disease. PFE shares are consolidating after recent moves. Track the latest developments here. Sickle cell disease is a group of inherited red blood cell disorders that affects hemoglobin, the protein that carries oxygen. It causes red blood cells…See the Story
Pfizer's Investigational Drug Flunks Late-Stage For Sickle Cell Disease - Pfizer (NYSE:PFE)
100% Center coverage: 2 sources
Maryland · MarylandExciting News: the Maryland Department of Health has officially accredited SCDAA’s Community Health Worker Training! This accolade will allow our program to have an even bigger impact in the state. Students who have successfully completed our training program can now apply for CHW certification with the Maryland Department of Health. Congrats to our CHW team on this accomplishment! The post SCDAA’s CHW Training Program Accredited by Maryland app…Read Article
SCDAA's CHW Training Program Accredited by Maryland - Sickle Cell Disease Association of America Inc.
You've scrolled to the bottom of the feed, there are no more stories.
